<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Vries, B.B.A. de</title>
    <link>http://repub.eur.nl/res/aut/3788/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Autosomal dominant inheritance of cardiac valves anomalies in two families: Extended spectrum of left-ventricular outflow tract obstruction (Article)</title>
      <link>http://repub.eur.nl/res/pub/18519/</link>
      <pubDate>2009-02-01T00:00:00Z</pubDate>
      <description>Only a limited number of families with clear monogenic inheritance of nonsyndromic forms of congenital valve defects have been described. We describe two multiplex pedigrees with a similar nonsyndromic form of heart valve anomalies that segregate as an autosomal dominant condition. The first family is a three-generation pedigree with 10 family members affected with congenital defects of the cardiac valves, including six patients with aortic stenosis and/or aortic regurgitation. Pulmonary and/or tricuspid valve abnormalities were present in three patients, and ventricular septal defect (VSD) was present in two patients. The second family consists of 11 patients in three generations with aortic valve stenosis in seven patients, defects of the pulmonary valves in two patients, and atrial septal defect (ASD) in two patients. Incomplete penetrance was observed in both families. Although left-ventricular outflow tract obstruction was present in most family members, the co-occurrence with pulmonary valve abnormalities and septal defects in both families is uncommon. These families provide evidence that left-sided obstructive defects and thoracic aortic aneurysm may be accompanied by right-sided defects, and even septal defects. These families might be instrumental in identifying genes involved in cardiac valve morphogenesis and malformation.</description>
    </item> <item>
      <title>Mutations in TITF-1 are associated with benign hereditary chorea (Article)</title>
      <link>http://repub.eur.nl/res/pub/9889/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>Benign hereditary chorea (BHC) (MIM 118700) is an autosomal dominant
      movement disorder. The early onset of symptoms (usually before the age of
      5 years) and the observation that in some BHC families the symptoms tend
      to decrease in adulthood suggests that the disorder results from a
      developmental disturbance of the brain. In contrast to Huntington disease
      (MIM 143100), BHC is non-progressive and patients have normal or slightly
      below normal intelligence. There is considerable inter- and intrafamilial
      variability, including dysarthria, axial dystonia and gait disturbances.
      Previously, we identified a locus for BHC on chromosome 14 and
      subsequently identified additional independent families linked to the same
      locus. Recombination analysis of all chromosome 14-linked families
      resulted initially in a reduction of the critical interval for the BHC
      gene to 8.4 cM between markers D14S49 and D14S278. More detailed analysis
      of the critical region in a small BHC family revealed a de novo deletion
      of 1.2 Mb harboring the TITF-1 gene, a homeodomain-containing
      transcription factor essential for the organogenesis of the lung, thyroid
      and the basal ganglia. Here we report evidence that mutations in TITF-1
      are associated with BHC.</description>
    </item> <item>
      <title>Benign hereditary chorea of early onset maps to chromosome 14q (Article)</title>
      <link>http://repub.eur.nl/res/pub/9227/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Benign hereditary chorea (BHC) is an autosomal dominant disorder
          characterized by an early-onset nonprogressive chorea. The early onset and
          the benign course distinguishes BHC from the more common Huntington
          disease (HD). Previous studies on families with BHC have shown that BHC
          and HD are not allelic. We studied a large Dutch kindred with BHC and
          obtained strong evidence for linkage between the disorder and markers on
          chromosome 14q (maximum LOD score 6.32 at recombination fraction 0). The
          BHC locus in this family was located between markers D14S49 and D14S1064,
          a region spanning approximately 20.6 cM that contains several interesting
          candidate genes involved in the development and/or maintenance of the CNS:
          glia maturation factor-beta, GTP cyclohydrolase 1 and the survival of
          motor neurons (SMN)-interacting protein 1. The mapping of the BHC locus to
          14q is a first step toward identification of the gene involved, which
          might, subsequently, shed light on the pathogenesis of this and other
          choreatic disorders.</description>
    </item> <item>
      <title>Dilemmas in counselling females with the fragile X syndrome (Article)</title>
      <link>http://repub.eur.nl/res/pub/9052/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>The dilemmas in counselling a mildly retarded female with the fragile X
          syndrome and her retarded partner are presented. The fragile X syndrome is
          an X linked mental retardation disorder that affects males and, often less
          severely, females. Affected females have an increased risk of having
          affected offspring. The counselling of this couple was complicated by
          their impaired comprehension which subsequently impaired their thinking on
          the different options. The woman became pregnant and underwent CVS, which
          showed an affected male fetus. The pregnancy was terminated. Whether
          nondirective counselling for this couple was the appropriate method is
          discussed and the importance of a system oriented approach, through
          involving relatives, is stressed.</description>
    </item> <item>
      <title>Noninvasive test for fragile X syndrome, using hair root analysis (Article)</title>
      <link>http://repub.eur.nl/res/pub/9115/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>Identification of the FMR1 gene and the repeat-amplification mechanism
          causing fragile X syndrome led to development of reliable DNA-based
          diagnostic methods, including Southern blot hybridization and PCR. Both
          methods are performed on DNA isolated from peripheral blood cells and
          measure the repeat size in FMR1. Using an immunocytochemical technique on
          blood smears, we recently developed a novel test for identification of
          patients with fragile X syndrome. This method, also called "antibody
          test," uses monoclonal antibodies against the FMR1 gene product (FMRP) and
          is based on absence of FMRP in patients' cells. Here we describe a new
          diagnostic test to identify male patients with fragile X syndrome, on the
          basis of lack of FMRP in their hair roots. Expression of FMRP in hair
          roots was studied by use of an FMRP-specific antibody test, and the
          percentage of FMRP-expressing hair roots in controls and in male fragile X
          patients was determined. Control individuals showed clear expression of
          FMRP in nearly every hair root, whereas male fragile X patients lacked
          expression of FMRP in almost all their hair roots. Mentally retarded
          female patients with a full mutation showed FMRP expression in only some
          of their hair roots (&lt;55%), and no overlap with normal female controls was
          observed. The advantages of this test are (1) plucking of hair follicles
          does no appreciable harm to the mentally retarded patient, (2) hairs can
          be sent in a simple envelope to a diagnostic center, and (3) the result of
          the test is available within 5 h of plucking. In addition, this test
          enabled us to identify two fragile X patients who did not show the full
          mutation by analysis of DNA isolated from blood cells.</description>
    </item> <item>
      <title>Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group (Article)</title>
      <link>http://repub.eur.nl/res/pub/8723/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>The fragile X syndrome is an X-linked mental retardation disorder caused
          by an expanded CGG repeat in the first exon of the fragile X mental
          retardation (FMR1) gene. Its frequency, X-linked inheritance, and
          consequences for relatives all prompt for diagnosis of this disorder on a
          large scale in all affected individuals. A screening for the fragile X
          syndrome has been conducted in a representative sample of 3,352
          individuals in schools and institutes for the mentally retarded in the
          southwestern Netherlands, by use of a brief physical examination and the
          DNA test. The attitudes and reactions of (non)consenting parents/guardians
          were studied by (pre- and posttest) questionnaires. A total of 2,189
          individuals (65%) were eligible for testing, since they had no valid
          diagnosis, cerebral palsy, or a previous test for the FMR1 gene mutation.
          Seventy percent (1,531/2,189) of the parents/guardians consented to
          testing. Besides 32 previously diagnosed fragile X patients, 11 new
          patients (9 males and 2 females) were diagnosed. Scoring of physical
          features was effective in preselection, especially for males (sensitivity
          .91 and specificity .92). Major motives to participate in the screening
          were the wish to obtain a diagnosis (82%), the hereditary implications
          (80%), and the support of research into mental retardation (81%).
          Thirty-four percent of the parents/guardians will seek additional
          diagnostic workup after exclusion of the fragile X syndrome. The
          prevalence of the fragile X syndrome was estimated at 1/ 6,045 for males
          (95% confidence interval 1/9,981-1/ 3,851). On the basis of the actual
          number of diagnosed cases in the Netherlands, it is estimated that &gt;50% of
          the fragile X cases are undiagnosed at present.</description>
    </item>
  </channel>
</rss>